Retrospective cohort study utilizing COVIREGI-JP to evaluate the efficacy of tocilizumab for severe COVID-19 pneumonia

Retrospective cohort study utilizing COVIREGI-JP to evaluate the efficacy of tocilizumab for severe COVID-19 pneumonia - SL43051

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000043622

Enrollment

248

Registered

2021-03-16

Start date

2021-03-16

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: [Tocilizumab population in JA42434 study] 1)Patients administered with Tocilizumab in JA42434 study [COVIREGI-JP Cohort] 1)Aged 18 years or older at the onset of COVID-19 2)Hospitalized between May 11, 2020 to Nov 18, 2020

Exclusion criteria

Exclusion criteria: [COVIREGI-JP cohort] 1)Pregnant women 2)Patients administered with any of the below during hospitalization - Sarilumab - Baricitinib

Design outcomes

Primary

Measure	Time frame
Time until discharge or waiting for discharge (with normal body temperature and respiratory rate, stable oxygen saturation under ambient air or oxygenation of 2 L or less)	—

Secondary

Measure	Time frame
7-point scale clinical categorization	—

Countries

Japan

Contacts

Public ContactNoriaki Matsunaga

National Center for Global Health and Medicine Disease Control and Prevention Center

registry.covid@hosp.ncgm.go.jp03-3202-7181

Outcome results